Study details
Enrolling now
Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
Jon Simmons
NCT IDNCT04445285ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
44
Study length
about 1.8 years
Ages
18+
Locations
1 site in AL
What this study is about
This trial is testing if giving a medication called rhDNase to people with COVID-19 who are having trouble breathing will make them safer and reduce the risk of dying within 28 days. The treatment involves nebulized Dornase Alpha (rhDNase).
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take 0.9%sodium chloride
- 2.Take Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
sodium chloride
Drug routes
oral (Oral Tablet)
Body systems
Infectious